Please upgrade your browser.
Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
EUSA Pharma (EUSA) welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud MÃ©jean, MD, PhD, of the HÃ´pital EuropÃ©en Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P < .0001). Median progression-free survival was 11.6 vs 8.4 months (HR = 0.82, P = not significant). The objective response rate was 41.6% vs 26.5% (P < .0001). The efficacy of the combination was not established in patients with favorable-risk disease.
Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.
A new study published in JAMA Internal Medicine suggests those who frequently eat organic foods may have a lower risk of developing cancer.
Colon and kidney cancer and lymphoma were among the types of cancer for which the correlation was strongest.
Wakame seaweed may have cancer-fighting properties. A study found that specific compounds extracted from the seaweed were effective at inhibiting the growth of colon and kidney cancer cells.
ESMO is only 7 days away. Here is an inside look at some of the trials that will be discussed.
Cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.
|NeonCRM by Neon One|